Annual report for Shilpa Medicare Ltd. for FY-2022
24-05-2022
SHILPA MEDICARE LTD. - 530549 - Appointment of Company Secretary and Compliance Officer
Appointment of Company Secretary & Compliance Officer23-05-2022
SHILPA MEDICARE LTD. - 530549 - Board recommends Dividend
Shilpa Medicare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 23, 2022, inter alia, has considered and approved the following: - Recommendation of Dividend:Payment of dividend of Rs. 1.10/- (110%) per equity share of face value of Rs. 1/- each for the financial year 2021-2022, subject to approval of members in the ensuing Annual General Meeting.23-05-2022
SHILPA MEDICARE LTD. - 530549 - Board Meeting Outcome for Outcome Of The Board Meeting
With reference to the captioned subject we hereby wish to inform you that the Board at its meeting held today i.e., on 23 May 2022 has inter alia considered and approved the following: 1. Approval of Financial Statements 2. Recommendation of Dividend 3. Update on Slump sale of Active Pharmaceutical Ingredient Business of the Company 4. Fund Raising plans in Shilpa Pharma Lifesciences Limited (A wholly owned subsidiary) by way of Initial Public offerings 5. Appointment of Company Secretary & Compliance Officer This is for your information and necessary records.23-05-2022
SHILPA MEDICARE LTD. - 530549 - Outcome Of The Board Meeting (Audited Financial Results)
The audited financial results (Standalone and Consolidated) for the quarter and year ended 31 March 2022, pursuant to Regulation 33 (3) of Listing Regulations. The copy of the same including statement of assets and liabilities, statement of cash flows along with the Auditors'' Report with unmodified opinion and a declaration to the effect that the Auditors have given unmodified opinion on the Audited financial result (Standalone and Consolidated) for the year ended 31 March 2022 (Please refer Annexure 1)23-05-2022
SHILPA MEDICARE LTD. - 530549 - Board to consider FY22 Results & Dividend on May 23, 2022
Shilpa Medicare Ltd has informed BSE that the Meeting of the Board of Directors of the Company is scheduled on May 23, 2022 inter alia to transact the following business items :1. Approval of the Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and the financial year ended March 31, 2022.2. Recommendation of Dividend, if any for the financial Year ended March 31, 2022.16-05-2022
SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2022 ,inter alia, to consider and approve 1. Approval of the Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and the financial year ended 31 March 2022 2. Recommendation of Dividend, if any for the financial Year ended 31 March 202216-05-2022
SHILPA MEDICARE LTD. - 530549 - US FDA Inspection Of Shilpa Medicare Limited, Unit VII, Analytical Services Division
This is to inform you that the Company's recently started Analytical Services Division situated on first Floor of Unit 7, Nacharam, Hyderabad, Telangana was inspected by US FDA during 26 Apr 2022 to 29 Apr 2022.02-05-2022
SHILPA MEDICARE LTD. - 530549 - Notice Of The National Company Law Tribunal (Tribunal) Convened Meeting Of The Equity Shareholders, Secured Creditors And Trade Creditors Of The Company.
Notice of the National Company Law Tribunal (Tribunal) Convened Meeting of the Equity Shareholders, Secured Creditors and Trade Creditors of the Company.26-04-2022
SHILPA MEDICARE LTD. - 530549 - Notice Of The National Company Law Appellate Tribunal (Tribunal) Convened Meeting Of The Equity Shareholders Of The Company.
By an order dated the 08th April 2022, the Bengaluru Bench of the Hon'ble National Company Law Tribunal, has directed to convene a meeting of Equity Shareholders, Trade Creditors and Secured Creditors of Shilpa Medicare Limited (Company) for the purpose of considering, and if thought fit, approving with or without modification, the Scheme of Amalgamation between INM Technologies Private Limited (Transferor Company) and Shilpa Medicare Limited (Transferee Company) and their respective Shareholders, Trade Creditors and Secured Creditors. In this regard, the meeting of the Equity Shareholders, Trade Creditors and Secured Creditors of the Company has been scheduled on 27 May 2022.25-04-2022